Compare iShares MSCI Malaysia ETF (EWM) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Malaysia ETF vs Neurocrine Biosciences Inc — how do they compare? iShares MSCI Malaysia ETF trades at $28.07, while Neurocrine Biosciences Inc trades at $157.49 (market cap $16.76B). Which is the better fit depends on your goals.
| EWM | NBIX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $30.42 | $185.50 |
52-Week Low | $24.73 | $123.10 |
Market Cap | — | $16.76B |
Enterprise Value | — | $16.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWM (iShares MSCI Malaysia ETF) trades at $28.18, up 0.28% with a bullish technical signal from moving averages. The ETF offers concentrated exposure to Malaysia's financial (54%) and industrial (21%) sectors, benefiting from data center expansion and tourism initiatives. Key support and resistance cluster around $28, with neutral oscillators suggesting balanced momentum.
Outlook remains positive due to Malaysia's structural growth drivers, though financial ratios are unavailable. Risks include energy supply constraints and regional currency volatility. Institutional sentiment leans bullish with 11 buy signals, but investors should monitor Malaysia's economic policies and global macro conditions.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Malaysia ETF
EWM tracks the MSCI Malaysia Index, providing exposure to the Malaysian equity market. It offers a diversified portfolio of large and mid-sized companies across various sectors in Malaysia.
Read more on EWM →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
